Tuesday, October 13, 2020
- Radiotherapy planning scans reveal breast cancer patients’ CVD risk (https://bit.ly/2FeoJiH)
- FDA OKs combination immunotherapy for first-line mesothelioma treatment (https://bit.ly/2Ff77mS)
- Apatinib plus gefitinib: Better PFS but more toxicity (https://bit.ly/34IyVsn)
- Atezolizumab strikes out in ovarian cancer (https://bit.ly/3iPjXG1)
@davidhenrymd. Dr. Henry reported being on the advisory board for Amgen, AMAG Pharmaceuticals, and Pharmacosmos. He reported institutional funding from the National Institutes of Health and FibroGen.